Investor Presentaiton

Investor Presentation First six months of 2018 Slide 9 Growth rate MAT volume growth rate 35% Monthly TRX share 100% Novo Nordisk's GLP-1 franchise on positive trajectory in the US with OzempicⓇ launched and 24% market volume growth USA GLP-1 market development USA GLP-1 volume market share MAT GLP-1 TRx volume (million) 10 Total TRX - NN GLP-1 VictozaⓇ OzempicⓇ dulaglutide exenatide USA GLP-1 NBRx market share VictozaⓇ OzempicⓇ dulaglutide exenatide NN GLP-1 albiglutide Weekly NBRX share albiglutide 50% 44.4% - 30% 8 80% 40% 25% 39.2% 16 60% 20% 43.2% 30% 41.8% 29.7% 15% 40% 20% 16.0% 41.5% 10% 2 20% 13.9% 10% 5% 14.7% 1.7% 0% 0% 0% May 2015 May May May May Jul 2018 2015 2018 2017 2018 Source: IQVIA NPA monthly, May 2018, NBRX-IQVIA LRX Weekly, week ending 20/07/2018 changing diabetes® novo nordisk

View entire presentation